+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

HIV Vaccines Market Research Report by Antibodies (Dicloxacillin, Fusidic Acid Ointment, and Gentamicin Ointment), Type, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 248 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 5533222
UP TO OFF until Dec 31st 2022
The Global HIV Vaccines Market size was estimated at USD 350.76 million in 2021, USD 487.38 million in 2022, and is projected to grow at a CAGR 39.20% to reach USD 2,552.37 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the HIV Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Antibodies, the market was studied across Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, and Mupirocin Ointment.
  • Based on Type, the market was studied across Acute Paronychia, Candidal Paronychia, Chronic Paronychia, and Pyogenic Paronychia.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for HIV Vaccines market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the HIV Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global HIV Vaccines Market, including AlphaVax, Inc., Antigen Express, Inc., Argo Therapeutics, Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., FIT Biotech, GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline plc, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Novartis AG, Oncolys Biopharma, PaxVax, Profectus Biosciences, Sanofi SA, and TVAX Biomedical.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global HIV Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global HIV Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HIV Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global HIV Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global HIV Vaccines Market?
6. What is the market share of the leading vendors in the Global HIV Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global HIV Vaccines Market?
Frequently Asked Questions about the Global HIV Vaccines Market

What is the estimated value of the Global HIV Vaccines Market?

The Global HIV Vaccines Market was estimated to be valued at $350.76 Million in 2021.

What is the growth rate of the Global HIV Vaccines Market?

The growth rate of the Global HIV Vaccines Market is 39.2%, with an estimated value of $2552.37 Million by 2027.

What is the forecasted size of the Global HIV Vaccines Market?

The Global HIV Vaccines Market is estimated to be worth $2552.37 Million by 2027.

Who are the key companies in the Global HIV Vaccines Market?

Key companies in the Global HIV Vaccines Market include AlphaVax, Inc., Antigen Express, Inc., Argo Therapeutics, Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., FIT Biotech and Genetic Immunity, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising R&D funding of HIV vaccine
5.1.1.2. Rising prevalence of HIV due to prostitution
5.1.1.3. Increasing awareness due to HIV prevention programs
5.1.2. Restraints
5.1.2.1. Contrivance of HIV drug resistance
5.1.3. Opportunities
5.1.3.1. Affordability of HIV medicines
5.1.3.2. Leading healthcare providers venturing into HIV sapce
5.1.4. Challenges
5.1.4.1. Commercialization of HIV vaccine
5.2. Cumulative Impact of COVID-19
6. HIV Vaccines Market, by Antibodies
6.1. Introduction
6.2. Dicloxacillin
6.3. Fusidic Acid Ointment
6.4. Gentamicin Ointment
6.5. Mupirocin Ointment
7. HIV Vaccines Market, by Type
7.1. Introduction
7.2. Acute Paronychia
7.3. Candidal Paronychia
7.4. Chronic Paronychia
7.5. Pyogenic Paronychia
8. Americas HIV Vaccines Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific HIV Vaccines Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa HIV Vaccines Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AlphaVax, Inc.
12.2. Antigen Express, Inc.
12.3. Argo Therapeutics
12.4. Argos Therapeutics, Inc.
12.5. Bionor Pharmaceuticals
12.6. Celldex Therapeutics, Inc.
12.7. Crucell N.V.
12.8. FIT Biotech
12.9. GeneCure LLC
12.10. Genetic Immunity, Inc.
12.11. GenVec, Inc.
12.12. GeoVax Labs, Inc.
12.13. GlaxoSmithKline plc
12.14. Immune Response BioPharma, Inc.
12.15. Inovio Pharmaceuticals, Inc.
12.16. Novartis AG
12.17. Oncolys Biopharma
12.18. PaxVax
12.19. Profectus Biosciences
12.20. Sanofi SA
12.21. TVAX Biomedical
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL HIV VACCINES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL HIV VACCINES MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL HIV VACCINES MARKET DYNAMICS
FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2021 VS 2027 (%)
FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2027
FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, 2019-2027 (USD MILLION)
FIGURE 18. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 20. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2027
FIGURE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, 2019-2027 (USD MILLION)
FIGURE 23. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 24. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, 2019-2027 (USD MILLION)
FIGURE 25. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, 2019-2027 (USD MILLION)
FIGURE 27. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, 2019-2027 (USD MILLION)
FIGURE 29. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 30. AMERICAS HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 32. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2027
FIGURE 34. ARGENTINA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. BRAZIL HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. CANADA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. MEXICO HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 40. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2027
FIGURE 42. ASIA-PACIFIC HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 44. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2027
FIGURE 46. AUSTRALIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. CHINA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. INDIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. INDONESIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. JAPAN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. MALAYSIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. PHILIPPINES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. SINGAPORE HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. SOUTH KOREA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. TAIWAN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. THAILAND HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 60. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2027
FIGURE 61. FRANCE HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. GERMANY HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. ITALY HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. NETHERLANDS HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. QATAR HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. RUSSIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. SAUDI ARABIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. SOUTH AFRICA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. SPAIN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. UNITED KINGDOM HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 72. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 73. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 74. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HIV VACCINES MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL HIV VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2019-2027 (USD MILLION)
TABLE 22. AMERICAS HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY STATE, 2019-2027 (USD MILLION)
TABLE 24. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2019-2027 (USD MILLION)
TABLE 28. AMERICAS HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. UNITED STATES HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 30. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2019-2027 (USD MILLION)
TABLE 33. AMERICAS HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. UNITED STATES HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 35. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2019-2027 (USD MILLION)
TABLE 38. AMERICAS HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. UNITED STATES HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 40. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 41. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2019-2027 (USD MILLION)
TABLE 43. AMERICAS HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 44. UNITED STATES HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY STATE, 2019-2027 (USD MILLION)
TABLE 45. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 47. AMERICAS HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 49. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 50. AMERICAS HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 51. ARGENTINA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 53. ARGENTINA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 54. BRAZIL HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 55. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 56. BRAZIL HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 57. CANADA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 59. CANADA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 60. MEXICO HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 61. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 62. MEXICO HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 63. UNITED STATES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 65. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 66. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 67. ASIA-PACIFIC HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 70. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 71. AUSTRALIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 72. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 73. AUSTRALIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 74. CHINA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 75. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 76. CHINA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 77. INDIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 79. INDIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 80. INDONESIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 82. INDONESIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 83. JAPAN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 85. JAPAN HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 86. MALAYSIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 87. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 88. MALAYSIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 89. PHILIPPINES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 91. PHILIPPINES HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 92. SINGAPORE HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 93. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 94. SINGAPORE HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 95. SOUTH KOREA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 96. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 97. SOUTH KOREA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 98. TAIWAN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 100. TAIWAN HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 101. THAILAND HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 102. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 103. THAILAND HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 108. FRANCE HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 109. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 110. FRANCE HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 111. GERMANY HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 112. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 113. GERMANY HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 114. ITALY HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 115. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 116. ITALY HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 117. NETHERLANDS HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 118. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 119. NETHERLANDS HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 120. QATAR HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 121. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 122. QATAR HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 123. RUSSIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 124. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 125. RUSSIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 126. SAUDI ARABIA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 127. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 128. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 129. SOUTH AFRICA HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 130. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 131. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 132. SPAIN HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 133. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 134. SPAIN HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 138. UNITED KINGDOM HIV VACCINES MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 139. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2019-2027 (USD MILLION)
TABLE 140. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 141. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 142. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 143. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 144. GLOBAL HIV VACCINES MARKET RANKING
TABLE 145. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2021
TABLE 146. GLOBAL HIV VACCINES MARKET MERGER & ACQUISITION
TABLE 147. GLOBAL HIV VACCINES MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 148. GLOBAL HIV VACCINES MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 149. GLOBAL HIV VACCINES MARKET INVESTMENT & FUNDING
TABLE 150. GLOBAL HIV VACCINES MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 151. GLOBAL HIV VACCINES MARKET: LICENSE & PRICING

Companies Mentioned

  • AlphaVax, Inc.
  • Antigen Express, Inc.
  • Argo Therapeutics
  • Argos Therapeutics, Inc.
  • Bionor Pharmaceuticals
  • Celldex Therapeutics, Inc.
  • Crucell N.V.
  • FIT Biotech
  • GeneCure LLC
  • Genetic Immunity, Inc.
  • GenVec, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline plc
  • Immune Response BioPharma, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Novartis AG
  • Oncolys Biopharma
  • PaxVax
  • Profectus Biosciences
  • Sanofi SA
  • TVAX Biomedical

Methodology

Loading
LOADING...